StockData
Repligen Corp logo

Repligen Corp (RGEN) stock

RGENNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 7/30132% above fair value
$172.67+10.49 (+6.47%)

Close on Nov 18, 2026Market cap $11.04BP/E –Yield –

Repligen price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Repligen's price to book ratio was 4.6× on Nov 11, 2026, against 4.6× a year earlier. Over the last 5 years it ranged from 3.2× to 8.5×, with a median of 4.6×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20264.6×+0.2
2025Dec 31, 20254.4×+0.4
2024Dec 31, 20244.0×−1.1
2023Dec 29, 20235.1×−0.0
2022Dec 30, 20225.1×−3.4
2021Dec 31, 20218.5×−0.4
2020Dec 31, 20209.0×+4.4
2019Dec 31, 20194.6×+0.8
2018Dec 31, 20183.8×+1.1
2017Dec 29, 20172.7×−3.5
2016Dec 30, 20166.3×−1.4
2015Dec 31, 20157.7×+2.0
2014Dec 31, 20145.7×+1.3
2013Dec 31, 20134.3×+1.5
2012Dec 31, 20122.9×+1.3
2011Dec 30, 20111.6×−0.6
2010Dec 31, 20102.2×–

More Repligen figures

See a number that looks wrong?